News Headlines

Display #
Takeda’s $5 Billion Bet On Ariad Pays Off With Accelerated Approval Of Lung Cancer Med
Tiny Parion Sciences Seals Dry Eye Drug Deal Worth $535 Million With Biotech Giant Shire
Agreement Reached After Novo Nordisk A/S is Accused of Disguising Salespeople and Dealing Kickbacks
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery
GlaxoSmithKline Injects $139 Million in Maryland Expansion
Neurotrope Alzheimer’s drug data fails to impress; shares crater
Widespread Vitamin D Deficiency Likely Due to Sunscreen Use, Increase of Chronic Diseases
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'
FDA approves Bayer’s Stivarga to treat most common liver cancer
Regeneron and Sanofi Announce Kevzara Biologics License Application Resubmission Accepted for Review by U.S. FDA
FDA Approves BioMarin’s drug for Batten Disease
Biotech Unicorn Moderna’s Vaccine Performs Well in First Human Trial
European Commission Extends Approval for Janssen’s Darzalex to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy
Sanofi Delivers Robust Q1 2017 Financial Results
FDA approves Novartis’ leukemia treatment
Italian-style coffee reduces the risk of prostate cancer
New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
Finance chief quits drugmaker Teva
Anthem moving ahead on 2018 Obamacare insurance plans
Merck cholesterol drug Vytorin faces competition from Impax, Teva generics
South Korea fines Novartis $49 million over kickbacks
FDA approves first treatment for a form of Batten disease
AstraZeneca Dumps Two Drugs From Pipeline
Mark Your Calendars: 4 Biotechs Facing FDA Decision Dates in May 2017
AbbVie profit beats on Humira demand
Celgene 1st quarter 2017 sales miss; expects psoriasis drug rebound
Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo
Merck divests Biosimilars business to Fresenius